Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old

Journal of the American Geriatrics Society

Volumn 52, Issue 11, 2004, Pages 1832-1839

  Boonen, Steven ^a   McClung, Michael R ^b   Eastell, Richard ^c   Fuleihan, Ghada El Hajj ^d   Barton, Ian P ^e   Delmas, Pierre ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b OREGON OSTEOPOROSIS CENTER   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^e PROCTER AND GAMBLE COMPANY   (United States)

^f EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Aged; Aged 80 and older; Fractures; Postmenopausal osteoporosis; Risedronate

Indexed keywords

CALCIUM; RISEDRONIC ACID; VITAMIN D; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE; ETIDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GERIATRIC CARE; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; VERTEBRA FRACTURE; BONE REMODELING; FEMALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PROPORTIONAL HAZARDS MODEL; RISK; SPINE FRACTURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE REMODELING; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PROPORTIONAL HAZARDS MODELS; RISK; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 4644346180     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52506.x     Document Type: Article

References (52)

1. Melton LJ 3rd, Lane AW, Cooper C et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:113-119.
2. Van der Klift M, De Laet CE, McCloskey EV et al. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2002;17:1051-1056.
3. European Prospective Osteoporosis Study (EPOS) Group. Incidence of verte-bral fracture in Europe: Results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002;17:716-724.
4. van Staa TP, Dennison EM, Leufkens HG et al. Epidemiology of fractures in England and Wales. Bone 2001;29:517-522.
5. Kanis JA, McCloskey EV. Epidemiology of vertebral Osteoporosis. Bone 1992;13(Suppl2):Sl-S10.
6. O'Neill TW, Felsenberg D, Varlow J et al. The prevalence of vertebral de-formity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-1018.
7. Autier P, Haentjens P, Bentin J et al. for the Belgian Hip Fracture Study Group. Costs induced by hip fractures: A prospective controlled study in Belgium. Osteoporos Int 2000;11:373-380.
8. Ismail AA, Cooper C, Felsenberg D et al. and the European Vertebral Osteo-porosis Study Group. Number and type of vertebral deformities: Epidemio-Iogical characteristics and relation to back pain and height loss. Osteoporos Int 1999;9:206-213.
9. Nevitt MC, Ettinger B, Black DM et al. The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Intern Med 1998;128:793-800.
10. Cummings SR, Kelsey JL, Nevitt MC et al. Epidemiology of Osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178-208.
11. Greendale GA, DeAmicis TA, Bucur A et al. A prospective study of the effect of fracture on measured physical performance: Results from the MacArthur Study-MAC. J Am Geriatr Soc 2000;48:546-549.
12. Gold DT. The clinical impact of vertebral fractures: Quality of life in women with Osteoporosis. Bone 1996;18(Suppl 3):185S-189S.
13. Jacobsen SJ, Cooper C, Gottlieb MS et al. Hospitalization with vertebral fracture among the aged: A national population-based study, 1986-89. Ep-idemiology 1992;3:515-518.
14. Papaioannou A, Adachi JD, Parkinson W et al. Lengthy hospitalization associated with vertebral fractures despite control for comorbid conditions. Osteoporos Int 2001;12:870-874.
15. Ensrud KE, Thompson DE, Cauley JA et al. for the Fracture Intervention Trial Research Group. Prevalent vertebral deformities predict mortality and hospi-talization in older women with low bone mass. J Am Geriatr Soc 2000;48:241-249.
16. Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996;156:2469-2475.
17. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.
18. Ross PD, Davis JW, Epstein RS et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-923.
19. Gunnes M, Mellstrom D, Johnell O. How well can a previous fracture indicate a new fracture? A questionnaire study of 29,802 postmenopausal women. Acta Orthop Scand 1998;69:508-512.
20. Black DM, Arden NK, Palermo L et al. for the Study of Osteoporotic Fractures Research Group. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 1999;14:821-828.
21. Ismail AA, Cockerill W, Cooper C et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: Results from the European Prospective Osteoporosis Study. Osteoporos Int 2001;12:85-90.
22. Cauley JA, Thompson DE, Ensrud KC et al. Risk of mortality following clin-ical fractures. Osteoporos Int 2000;11:556-561.
23. Kado DM, Browner WS, Palermo L et al. for the Study of Osteoporotic Frac-tures Research Group. Vertebral fractures and mortality in older women: A prospective study. Arch Intern Med 1999;159:1215-1220.
24. Cooper C, Atkinson EJ, Jacobsen SJ et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-1005.
25. Ismail AA, O'Neill TW, Cooper C et al. Mortality associated with vertebral deformity in men and women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 1998;8:291-297.
26. Ettinger MP. Aging bone and Osteoporosis: Strategies for preventing fractures in the elderly. Arch Intern Med 2003;163:2237-2246.
27. Freedman KB, Kaplan FS, Bilker WB et al. Treatment of Osteoporosis: Are physicians missing an opportunity? J Bone Joint Surg Am 2000;82-A:1063-1070.
28. Kamel HK, Hussain MS, Tariq S et al. Failure to diagnose and treat os-teoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000;109:326-328.
29. Gehlbach SH, Bigelow C, Heimisdottir M et al. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000;11:577-582.
30. Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteo-porotic fracture. Ann Rheum Dis 1998;57:378-379.
31. Kamel HK, Duthie EH. The underuse of therapy in the secondary prevention of hip fractures. Drugs Aging 2002;19:1-10.
32. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-1642.
33. Chapuy MC, Pamphile R, Paris E et al. Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk. The Decalyos II Study. Osteoporos Int2002;13:257-264.
34. Harris ST, Watts NB, Genant HK et al. for the Vertebral Efficacy with Rise-dronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteo-porosis: A randomized controlled trial. JAMA 1999;282:1344-1352.
35. Reginster J, Minne HW, Sorensen OH et al. on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal Osteoporosis. Osteoporos Int 2000;11:83-91.
36. McClung MR, Geusens P, Miller PD et al. for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340.
37. Genant HK, Wu CY, van Kuijk C et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148.
38. Cummings S, Black D, Thompson D et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
39. Black DM, Cummings SR, Karpf DB et al. for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
40. Looker AC, Wahner HW, Dunn WL et al. Updated data on proximal femur bone mineral levels of U. S. adults. Osteoporos Int 1998;8:468-189.
41. Gumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997;12:1321-1329.
42. Recker RR, Hinders S, Davies KM et al. Correcting calcium nutritional de-ficiency prevents spine fractures in elderly women. J Bone Miner Res 1996;11:1961-1966.
43. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-285.
44. Watts NB, Josse RG, Hamdy RC et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003;88:542-549.
45. Ettinger B, Black DM, Mitlak BH et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with Osteoporosis treated with ra-loxifene: Results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
46. Black DM, Reiss TF, Nevitt MC et al. for the Fracture Intervention Trial Research Group. Design of the fracture intervention trial. Osteoporos Int 1993;3(Suppl 3):S29-S39.
47. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
48. Melton LJ 3rd, Riggs BL Hip fracture: A disease and an accident. In: Uhthoff HK, Stahl E, eds. Current Concepts of Bone Fragility. Berlin: Springer-Verlag, 1986, pp 385-389.
49. Melton LJ 3rd, Kan SH, Warmer HW et al. Lifetime fracture risk: An approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 1988;41:985-994.
50. Colina RE, Smith M, Kikendall JW et al. A new probable increasing cause of esophageal ulceration. Alendronate Am J Gastroenterol 1997;92:704-706.
51. De Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021.
52. Ettinger B, Pressman A, Schein J et al. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Man Care Pharm 1998;4:488-492.